Showing 1136 results
-
Press release /Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus…
-
Press release /The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression…
-
Press release /Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early…
-
Press release /In the Phase III RAINBOW study, despite marginally missing statistical significance for the primary endpoint of demonstrating superiority of Lucentis® to laser surgery, Lucentis was shown to be…
-
Press release /Children and adolescents with multiple sclerosis (MS) experience more frequent and often more severe relapses than adults with the disease, hindering their development and ability to take part in…
-
Press release /Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (…
-
Press release /33 abstracts from the leading MS portfolio include data for Gilenya® (fingolimod), and investigational drugs siponimod (BAF312) and ofatumumab (OMB157) New research will be presented on…
-
Press release /Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…
-
Press release /Presentation of results from the Kisqali® (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer New MONALEESA-2 analyses…
-
Press release /Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar…